WALLWST.SNUMBERSN

Home
Stocks
IKT
Gross profit

Inhibikase Therapeutics (IKT) Gross Profit

General

Overview
Financials

Market data

Price
Market cap
Shares outstanding
Beta
Moving average
RSI
Volatility
ATR

Dividend

Dividend per share
Dividend yield
Payout ratio
Dividends paid

Profitability

Revenue
Gross profit
Operating profit
Net income
EPS

Efficiency

Gross margin
Operating margin
Net margin
EBIT
EBITDA
ROA
ROE
Interest coverage ratio

Valuation

PE ratio
PB ratio
PS ratio
EV/EBITDA
Enterprise value

Equity

Shareholders equity
Book value
Retained earnings
Working capital

Assets

Total assets
Current assets
Non current assets
Cash and cash equivalents
Accounts receivable
Inventory

Liabilities

Total liabilities
Current liabilities
Long term liabilities
Accounts payable
Total debt
Short term debt
Long term debt

Liquidity

Debt to equity
Current ratio
Quick ratio

Expense

Total expenses
Operating expenses
Cost of goods sold
Selling, general & administrative expenses
Depreciation and amortization
Interest expense
Income tax

Cash Flow

Cash from operations
Cash from investing
Cash from financing
CAPEX
Free cash flow

Risk & Stability

Piotroski F score
Altman Z score

There is no historical data available for Inhibikase Therapeutics Gross Profit

Pricing FAQ Terms and conditions Privacy policy Contact us

© 2024 WallStreetNumbers